adult focal onset seizures

Oppenheimer has downgraded Marinus Pharmaceuticals Inc (NASDAQ: MRNS) to Perform after the company's first Phase 3 epilepsy study for adult focal onset seizures failed to meet its primary endpoint. Even though company indicated there were certain sub-demographics of better responders in the greater...